Actively Recruiting

Phase 1
Phase 2
Age: 20Years - 40Years
FEMALE
NCT07115082

Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

Led by Yan Hongli · Updated on 2025-08-11

50

Participants Needed

1

Research Sites

75 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.

CONDITIONS

Official Title

Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

Who Can Participate

Age: 20Years - 40Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 20 to less than 40 years with normal karyotype
  • Oligo/amenorrhea lasting at least 4 months
  • Elevated FSH level greater than 25 IU/l on two occasions more than 4 weeks apart
  • No history of stem cell therapy or hormone treatments within the previous 3 months
  • Voluntary participation with signed informed consent
Not Eligible

You will not qualify if you...

  • Unable to follow the treatment observation process required by the trial
  • Genetic diseases, chromosomal abnormalities, or genetic deficiencies causing POI
  • Presence of breast, uterine, ovarian, or other benign or malignant tumors
  • Allergic history to drugs or other substances
  • Genetic disorders such as Turner's syndrome or congenital reproductive organ malformations
  • Prior ovariectomy or organic gynecological diseases
  • Other gynecological endocrine diseases such as polycystic ovary syndrome
  • Severe functional impairment of vital organs
  • High risk for venous thromboembolism or coagulation abnormalities
  • Considered inappropriate for participation by attending doctor

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Changhai Hospital

Shanghai, China, 200433

Actively Recruiting

Loading map...

Research Team

H

Hongli Yan PhD, Professor, Reproductive Medici

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency | DecenTrialz